首页> 外文OA文献 >An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

【2h】

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

机译：晚期或非晚期非小细胞肺癌患者一线治疗的顺铂和培美曲塞联合或不联合西妥珠单抗（IMC-A12）作为开放式，多中心，II期临床研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Novello Silvia; Scagliotti Giorgio; de Castro Gilberto; Kiyik Murat; Kowalyszyn Rubén; Deppermann Karl-Matthias; Arriola Edurne; Bosquee Lionel; Novosiadly Ruslan D.; Nguyen Tuan S.; Forest Amelie; Tang Shande; Kambhampati Siva Rama Prasad; Cosaert Jan; Reck Martin;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer [J] . Silvia Novello, Giorgio Scagliotti, Gilberto de Castro, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第2期

机译：开放标签，多中心，随机，双顺铂和培养基（IMC-A12）作为先进的非小细胞肺癌患者的一线治疗
2. An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer [J] . Waller Cornelius F., Vynnychenko Ihor, Bondarenko Igor, Clinical lung cancer . 2015,第2期

机译：甲磺酸依瑞布林联合培美曲塞和单独使用培美曲塞作为二线治疗在晚期非鳞状非小细胞肺癌患者中的开放标签，多中心，随机Ib / II期研究
3. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer [J] . Zinner Ralph G., Obasaju Coleman K., Spigel David R., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第1期

机译：释放：随机，开放标签，第一线Pemetrexed Plus Carboplatin的第三阶段研究，然后进行维持培养型Pemetrexed与PACLitaxel Plus Carboplatin Plus Bevacizumab，然后在患者中进行维护贝伐单抗，患者患者先进的非小细胞肺癌
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. PRONOUNCE: Randomized Open-Label Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer [O] . Ralph G. Zinner, Coleman K. Obasaju, David R. Spigel, -1

机译：代名词：晚期非鳞状非小细胞肺癌患者一线培美曲塞+卡铂联合维持培美曲塞与紫杉醇+卡铂+贝伐单抗+贝伐珠单抗一线治疗的随机开放标签III期研究
7. An open-label, multicenter, randomized, phase II study of Cisplatin and Pemetrexed with or without Cixutumumab (IMC-A12) as a first-line therapy in patients with advanced nonsquamous non-small cell lung cancer. [O] . Novello, Silvia, Scagliotti, Giorgio, De Castro, Gilberto, 2017

机译：一项开放标签，多中心，随机，II期的顺铂和培美曲塞研究，有或没有Cixutumumab（ImC-a12）作为晚期非鳞状非小细胞肺癌患者的一线治疗。

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅